Jul 2, 2026
Jul 2, 2026
Jul 2, 2026
Jul 2, 2026
Jul 2, 2026
Jul 2, 2026
Jul 2, 2026
Jul 2, 2026
Moderna's pivot from 'vaccine' to 'individualized neoantigen therapy' is a strategic move to dodge skepticism. But can rebranding truly overcome public and regulatory hurdles?